TACT2 is a clinical trial to determine whether intravenous (IV) Na2EDTA chelation therapy with oral (by mouth) multivitamins will reduce the risk of major cardiovascular events (such as stroke and heart attack) in patients who have already had a heart attack and who also have type 2 diabetes.
The chelation therapy used in the TACT2 study consists of up to 40 treatments through a vein in your arm (infusion) of a solution of disodium ethylene diamine tetra-acetic acid (Na2EDTA or disodium EDTA), vitamins, and other dissolved materials. Disodium EDTA is thought to bind toxic metals in the body, including lead and cadmium, that may contribute to the development of heart disease.
You may qualify if:
- Over the Age of 50
- Have been Diagnosed with a Heart Attack
- Have been Diagnosed with Diabetes
Benefits of this Research Study
- Free study-related care
- Study medication
- Compensation for Time and Travel for those who qualify